151 related articles for article (PubMed ID: 18440306)
21. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
22. The JNK-dependent CaMK pathway restrains the reversion of committed cells during osteoclast differentiation.
Chang EJ; Ha J; Huang H; Kim HJ; Woo JH; Lee Y; Lee ZH; Kim JH; Kim HH
J Cell Sci; 2008 Aug; 121(Pt 15):2555-64. PubMed ID: 18650497
[TBL] [Abstract][Full Text] [Related]
23. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis.
Fujita S; Mukai T; Mito T; Kodama S; Nagasu A; Kittaka M; Sone T; Ueki Y; Morita Y
Bone; 2018 Jan; 106():156-166. PubMed ID: 29055830
[TBL] [Abstract][Full Text] [Related]
25. Sexual Dimorphism in MAPK-Activated Protein Kinase-2 (MK2) Regulation of RANKL-Induced Osteoclastogenesis in Osteoclast Progenitor Subpopulations.
Herbert BA; Valerio MS; Gaestel M; Kirkwood KL
PLoS One; 2015; 10(5):e0125387. PubMed ID: 25946081
[TBL] [Abstract][Full Text] [Related]
26. Self-assembled RANK induces osteoclastogenesis ligand-independently.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 Nov; 20(11):2053-60. PubMed ID: 16234979
[TBL] [Abstract][Full Text] [Related]
27. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
Cheng CP; Sheu MJ; Sytwu HK; Chang DM
Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
[TBL] [Abstract][Full Text] [Related]
28. Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.
Kittaka M; Yoshimoto T; Schlosser C; Rottapel R; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2020 Feb; 35(2):382-395. PubMed ID: 31613396
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
30. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
Jia P; He YF; Gao C; Du HB; Hu ZY; Feng XQ; Li BY; Zhang ZL; Xu YJ; Lin H
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2214-8. PubMed ID: 23158430
[TBL] [Abstract][Full Text] [Related]
31. Dried plum polyphenols inhibit osteoclastogenesis by downregulating NFATc1 and inflammatory mediators.
Bu SY; Lerner M; Stoecker BJ; Boldrin E; Brackett DJ; Lucas EA; Smith BJ
Calcif Tissue Int; 2008 Jun; 82(6):475-88. PubMed ID: 18509698
[TBL] [Abstract][Full Text] [Related]
32. Effect of fluoride on osteocyte-driven osteoclastic differentiation.
Jiang N; Guo F; Xu W; Zhang Z; Jin H; Shi L; Zhang X; Gao J; Xu H
Toxicology; 2020 Apr; 436():152429. PubMed ID: 32156525
[TBL] [Abstract][Full Text] [Related]
33. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
34. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
35. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
37. ATF3 modulates calcium signaling in osteoclast differentiation and activity by associating with c-Fos and NFATc1 proteins.
Jeong BC; Kim JH; Kim K; Kim I; Seong S; Kim N
Bone; 2017 Feb; 95():33-40. PubMed ID: 27829167
[TBL] [Abstract][Full Text] [Related]
38. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
[TBL] [Abstract][Full Text] [Related]
39. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
40. Ampelopsis brevipedunculata extract prevents bone loss by inhibiting osteoclastogenesis in vitro and in vivo.
Kim JY; Park SH; Oh HM; Kwak SC; Baek JM; Lee MS; Rho MC; Oh J
Molecules; 2014 Nov; 19(11):18465-78. PubMed ID: 25397737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
